Abstract
The behavioral and neurochemical consequences of the intrastriatal administration of 1-methyl-4-phenylpyridinium ion (MPP+), the toxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), were evaluated using the shuttlebox avoidance paradigm. MPP+ caused a significant depletion of striatal dopamine and significant disruption of shuttlebox performance. L-Dopa administration reversed both the dopamine depletion and the behavioral deficits. These observations are discussed in reference to the rodent-MPTP model of Parkinson's disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
